LOGAN CAROLYN J 4
4 · SALIX PHARMACEUTICALS LTD · Filed Dec 21, 2012
Insider Transaction Report
Form 4
LOGAN CAROLYN J
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Option to Buy Common Stock
2012-12-20−33,750→ 0 totalExercise: $7.60Exp: 2013-07-24→ Common Stock (33,750 underlying) - Exercise/Conversion
Common Stock
2012-12-20$7.60/sh+33,750$256,500→ 660,881 total - Sale
Common Stock
2012-12-20$42.27/sh−25,000$1,056,673→ 635,881 total
Holdings
- 400,000(indirect: by GRAT)
Common Stock
- 44,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (44,000 underlying) - 65,625
Option to Buy Common Stock
Exercise: $18.87Exp: 2014-06-17→ Common Stock (65,625 underlying) - 33,750
Option to Buy Common Stock
Exercise: $18.87Exp: 2014-06-17→ Common Stock (33,750 underlying)
Footnotes (3)
- [F1]This sale was pursuant to a Rule 10b5-1 Sales Plan dated December 4, 2012, which is intended to comply with Rule 10b5-1.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.51, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F3]Options are 100% vested.